TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hydrogen Therapy in Patients With Moderate Covid-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient ≥18 years old~2. Suspicion of SARS CoV-2 infection based on clinical signs AND (positive PCR OR positive serology OR suggestive abnormalities on lung-imaging modalities)~3. Hospitalized patients with SpO2 ≤94% on room air requiring normobaric oxygen therapy with a nasal flow of O2 ≤ 6L / min to reach at least SaO2 ≥ 95%~4. Patient understanding and agreeing to comply with the planned study procedures~5. Patient affiliated with social security or beneficiary of such protection~6. Patient (or his legal representative) who has given his informed consent in writing before the start of any study procedure.~Exclusion Criteria:~1. Pregnant or parturient women~2. Ratio of spontaneous blood ALT/AST\> 5 times the normal upper limit.~3. Stage 4 of severe chronic kidney disease or requiring dialysis (i.e. eGFR \<30)~4. Early transfer to another hospital within 72 hours.~5. Contraindication to any study drug, including a known allergy~6. Uncontrolled and clinically significant heart disease, such as arrhythmias, angina pectoris or uncompensated congestive heart failure~7. Patients treated in ambulatory care (i.e. not hospitalized)~8. Females of childbearing potential, defined as a premenopausal female capable of becoming pregnant, and not using an highly effective form of birth control.~9. Participant involved in another interventional clinical study~10. Person deprived of liberty by judicial order~11. Person under guardianship or curatorship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Non-CE Marked Intermittent Catheters.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Minimum 18 years of age and with full legal capacity~* Daily intermittent catheterization for bladder management, with at least two catheters used on average pr. day, during the last 3 months~* Ability to self-catheterize~* Written informed consent, signed letter of authority and signed secrecy agreement given~Exclusion Criteria:~* Participation in any other clinical study during this investigation~* Symptoms of urinary tract infection as judged by the investigator~* Any know allergies towards ingredients in the products~* Relevant medical history that would prevent the subject from participation in the investigation (investigators judgement)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent catheter; SpeediCath® Standard male (Type: ACTIVE_COMPARATOR): Participants underwent two catheterizations with standard of care intermittent catheter: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 1 for males (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter Variant 1 for males: The first was performed by a trained nurse, the second by the participant later the same day.
- New intermittent catheter Variant 2 for males (Type: EXPERIMENTAL): Participants underwent two catheterizations with the new intermittent catheter Variant 2 for males: The first was performed by a trained nurse, the second by the participant later the same day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or females at least 18 years of age, of any ethnic origin~* Type 1 or 2 diabetes mellitus~* Pain score greater than or equal to 4 on the 11-point numeric pain rating scale~Exclusion Criteria:~* Neurologic disorders unrelated to diabetic neuropathy that may confuse or confound the assessment of neuropathic pain.~* Presence of severe pain associated with conditions other than diabetic peripheral neuropathy, that could confound the assessment or self-evaluation of pain due to DPN.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* o At least 18 years of age~  * Male or female patient who had DMEK within the past 1 to 7 weeks.~ * Patient is able and willing to administer eye drops.~ * Patient is able to comprehend and has signed the Informed Consent form.~ * Patient is likely to complete the 11-month study duration.~Exclusion Criteria:~* o A history of a previous rejection episode in the study eye~  * A patient exhibiting intraocular inflammation.~ * A patient with a known sensitivity to any of the ingredients in the study medications~ * A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study~ * A patient with abnormal eyelid function.~ * A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis.~ * Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled.~ * A patient with a history of non-compliance with using prescribed medication.~ * Patients who are pregnant or planning to become pregnant within the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preventative Treatment (Type: EXPERIMENTAL): Loteprednol etabonate ophthalmic suspension 0.25% dosed 4 times daily for 2 months, 3 times daily for one month, twice daily for one month, and once daily until the 1 year postop exam.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.~Inclusion Criteria:~* Received between 1 to 4 prior lines of therapy~* Measureable disease~* Men and women of childbearing potential (WOCBP) must be using two acceptable methods of contraception~* Men must agree to use a latex condom and a second form of birth control during sexual contact with WOCBP and must agree to not donate semen during study drug therapy~* Subjects must be willing to refrain from blood donations during study drug therapy~Exclusion Criteria:~* Subjects with non-secretory or oligo-secretory or light-chain only myeloma or active/prior plasma cell leukemia or known /suspect POEMS syndrome~* Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia~* Unable to take aspirin daily as prophylactic anticoagulation therapy. Prior history of inability to tolerate weekly 40 mg dexamethasone~* History of renal failure~* History of clinical significant thrombosis, such as treatment for thrombosis was required

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-901608 (Elotuzumab) 10mg (Type: EXPERIMENTAL): None
- BMS-901608 (Elotuzumab) 20mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient completed a previous double-blind plecanatide study and was compliant with the study requirements.~* Patient is in good health without unstable acute illness or exacerbation of an unstable chronic illness or chronic disease that may affect study assessments, particularly if there has been a significant change to health status since the previous plecanatide study.~Exclusion Criteria:~* Patient has had major surgery including laparoscopic procedures requiring general anesthesia within 60 days of Day 1.~* Patient has a medical history of hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.~* Patient has taken a protocol-prohibited drug without the appropriate washout period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- Plecanatide 3.0 mg (Type: EXPERIMENTAL): Plecanatide 3.0 mg, one tablet by mouth daily for 52 weeks
- Plecanatide 6.0 mg (Type: EXPERIMENTAL): Plecanatide 6.0 mg, one tablet by mouth daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of idiopathic PAH (formally known as PPH), or PAH associated with collagen vascular disease, anorexigen use, or HIV infection;~* Historical cardiac catheterization with the following hemodynamic criteria:~Mean pulmonary artery pressure greater than or equal to 25 mmHg; Pulmonary vascular resistance greater than 3 mmHg/L/min; Pulmonary capillary wedge pressure or left ventricular end diastolic pressure less than 15 mmHg;~* 6-minute walk distance of at least 150 meters, but no more than 450 meters;~* Total lung capacity greater than or equal to 70% and FEV1 greater than or equal to 65% of predicted normal;~Exclusion Criteria:~* Portopulmonary hypertension;~* Subjects with PAH due to or associated with coronary artery disease, left heart disease, interstitial lung disease, chronic obstructive pulmonary disease, veno-occlusive disease, chronic thromboembolic disease, or sleep apnea;~* Bosentan (Tracleer®), sildenafil (Viagra®), or chronic prostanoid therapy within 4 weeks of screening;~* Serum ALT or AST lab value that is greater than 1.5 times the upper limit of normal;~* Contraindication to treatment with an endothelin receptor antagonist;~* Subject with cardiovascular, hepatic, renal, hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that may adversely affect the safety of the subject;~* Participation in a clinical study involving another investigational drug within 4 weeks of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at screening or, if still lactating or actively breastfeeding at screening, must agree to temporarily cease giving breast milk to her infant(s)~* Participant has had a Major Depressive Episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 Axis I Disorders (SCID-I)~* Participant was \<=six months postpartum.~Key Exclusion Criteria:~* Active psychosis~* Attempted suicide associated with current episode of postpartum depression~* Medical history of seizures~* Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.~Note: suicidal ideation was not an exclusion. Other protocol-defined inclusion/exclusion criteria might apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAGE-217 15/20 mg Oral Solution (Type: EXPERIMENTAL): Participants received SAGE-217, 15 milligrams (mg), oral solution, twice daily (BID) for first 2 days followed by SAGE-217, 15 or 20 mg, oral solution, BID, starting on Day 3 for up to 14 days as tolerated.
- Part B: Placebo (Type: PLACEBO_COMPARATOR): Participants received SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.
- Part B: SAGE 217 30 mg Capsules (Type: EXPERIMENTAL): Participants received SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immune Response to Influenza Vaccine in ESRD Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- ESRD patients aged 18 years or older, who had been treated for more than one month of either thrice weekly on-line hemodiafiltration (HDF) or conventional high flux hemodialysis (HD), with a session dialyzer urea clearance (Kt/V urea) of 1.2 and greater, with a convection volume target of 20 L/session for the HDF group~Exclusion Criteria:~* Had received any vaccination within the previous four weeks, or influenza vaccination within six months~* Patient who reported upper respiratory tract symptoms within three days prior to the study vaccination~* A history of allergy to influenza vaccine or egg~* Thrombocytopenia~* In receipt of immunosuppressant medications, chemotherapy, or had immunodeficiency

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemodialysis (Type: ACTIVE_COMPARATOR): ESRD patients treated by hemodialysis
- Hemodiafiltration (Type: ACTIVE_COMPARATOR): ESRD patients treated by on-line hemodiafiltration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, nonsmoking, male and/or female subjects of non-childbearing potential.~* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.~* Total body weight \>50 kg (110 lbs).~Exclusion Criteria:~* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.~* An ALT or AST measurement \>2 times the ULN.~* 12-lead ECG demonstrating QTc \>450 msec or a QRS interval \>120 msec at Screening.~* Subjects at increased risk if dosed with moxifloxacin, according to the product label for moxifloxacin.~* History of risk factors of QT prolongation or torsades de pointes, congenital deafness and family history of sudden death.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Period 1: 960 mg tafamidis (Vyndaqel) (Type: EXPERIMENTAL): None
- Period 2: 400 mg moxifloxacin (Type: EXPERIMENTAL): 400 mg moxifloxacin
- Period 3: Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated glomerular filtration rate (eGFR) of 20 to \<60 mL/min/1.73m2~* Serum bicarbonate level of 12 to 20 mEq/L~Exclusion Criteria:~* Any level of low serum bicarbonate that, in the opinion of the Investigator, requires emergency intervention.~* Severe comorbid conditions other than chronic kidney disease.~* Chronic obstructive pulmonary disease.~* Anticipated changes in doses of any of the following drugs or drug classes: diuretics, non-ophthalmic carbonic anhydrase inhibitors, oral diabetes drugs, antihypertensive drugs, antacids, H2-blockers, or proton pump inhibitors.~* Excluded drugs or drug classes: insulin, non-daily or as needed diuretics, herbal products, dietary supplements, multivitamins, naturopathic remedies, sodium bicarbonate, potassium citrate, sodium citrate or other alkali therapy, non-steroidal anti-inflammatory drugs (NSAIDs), fiber supplements, laxatives, calcium and magnesium supplements, or electrolyte binders and other binder drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo-BID (Type: PLACEBO_COMPARATOR): Administered twice daily (BID) for 14 days
- TRC101 (1.5g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (3g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (4.5g BID) (Type: EXPERIMENTAL): Administered twice daily (BID) for 14 days
- TRC101 (6g QD) (Type: EXPERIMENTAL): Administered once daily (QD) for 14 days
- Placebo-QD (Type: PLACEBO_COMPARATOR): Administered once daily (QD) for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have completed the maintenance period of the P09-004 study.~* Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Open-label USL255 (Type: EXPERIMENTAL): Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Growth Hormone as Add-on Treatment in Severe Fibromyalgia With Low IGF-1 Serum Levels (56 Characters)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women greater than 18 years old with severe fibromyalgia and abnormally low IGF-1 levels included in a rehabilitation and psychological program and stable under standard intensive treatment for at least 6 months.~* All patients fulfilled the 1990 ACR diagnostic criteria (1) and had an IGF-1 level \<250 ng/mL (or 1 standard deviation bellow the mean value corresponding to age and body surface according to laboratory reference value).~* Other inclusion criteria were duration of fibromyalgia of 1 year or greater, pain in at least 16 (8 bilateral) of the 18 tender points and a score in the FIQ \> 75.~* The study was conducted in accordance with the Declaration of Helsinki and received the local institutional review board and Spanish Drug Agency (nº03-0456) approvals. All patients gave written informed consent prior to their inclusion in the study.~Exclusion Criteria:~* Disabling physical or mental status~* Previous or current malignancies, either active or inactive~* Intracranial space occupying lesion~* Any relevant endocrine disorder including diabetes mellitus~* History of another pituitary disorder~* Previous treatment with growth hormone~* Other systemic or joint inflammatory rheumatic conditions; and~* Known to be hypersensitive to somatropin or any of the excipients.~* Pregnant women, nursing mothers, or women with childbearing potential not using adequate contraceptive methods were also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete